Posted by ed_uk on January 2, 2006, at 6:24:20
In reply to A new MAOI, posted by ed_uk on January 2, 2006, at 5:11:28
Ladostigil is currently in phase II clinical trials for Alzheimer's disease. Of interest to us, ladostigil might in future be prescribed 'off label' in the treatment of depression, anxiety and cognitive disorders.
From the TEVA website......
'Ladostigil Tartrate (TV-3326) for Alzheimer's Disease
Ladostigil tartrate (TV-3326) is a novel compound developed for the treatment of Alzheimer's disease (AD) and other forms of dementia. It combines in one molecule three mechanisms of action: MAO-inhibition, cholinesterase inhibition and neuroprotective activity. The combination of these three activities in a single entity gives the molecule a unique profile: It targets both the cognitive impairment and the problematic behavioral disturbances, such as depression and anxiety, prevalent in AD, and also potentially modifies the course of the disease via its neuroprotective mechanism. The development of ladostigil tartrate is based on original research done in the Technion & the Hebrew University, in Israel.
Teva has acquired the exclusive world-wide license to all intellectual property related to.
The product Phase I studies with ladostigil have been completed and a phase IIa study has been recently initiated in Europe.'Ed
poster:ed_uk
thread:594285
URL: http://www.dr-bob.org/babble/20051231/msgs/594291.html